Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury
American Journal of Physical Medicine and Rehabilitation, ISSN: 0894-9115, Vol: 82, Issue: 9, Page: 678-685
2003
- 66Citations
- 64Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations66
- Citation Indexes59
- 59
- CrossRef42
- Clinical Citations5
- PubMed Guidelines5
- Policy Citations2
- Policy Citation2
- Captures64
- Readers64
- 64
Article Description
Objective: To determine differences between dalteparin and enoxaparin in patients with spinal cord injury. Design: This prospective, randomized, open-label study was performed as a multiple hospital trial in a large urban setting. A total of 100 patients with acute (<3 mo) spinal cord injury were recruited. A total of 95 patients met all inclusion criteria. Fifty received enoxaparin, and 45 received dalteparin. Main outcome measures included deep venous thrombosis, bleeding, compliance, Short Form-12 Health Status Survey, satisfaction, and medication/labor costs. Patients were randomized to receive 30 mg of enoxaparin subcutaneously every 12 hr or 5000 IU of dalteparin subcutaneously once daily. Prophylaxis was continued for 3 mo for motor-complete and 2 mo for motor-incomplete patients. Results: Six percent of the patients developed deep venous thrombosis while receiving enoxaparin and 4% while receiving dalteparin (χ = 0.44, df = 1, P = 0.51). Four percent developed bleeding while receiving dalteparin and 2% while receiving enoxaparin (χ = 0.13, df = 1, P = 0.72). No differences were noted in compliance, health status, or most of the satisfaction measures. It was, however, noted that after being discharged home, the patients receiving enoxaparin rated the shots significantly more inconvenient (two injections per day) compared with taking three pills per day, than those receiving dalteparin (one injection per day, P < 0.05). The cost of the medication was $1101/mo for enoxaparin (two injections per day) and $750/mo for dalteparin (one injection per day). Conclusion: Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0042943284&origin=inward; http://dx.doi.org/10.1097/01.phm.0000083671.27501.47; http://www.ncbi.nlm.nih.gov/pubmed/12960909; http://journals.lww.com/00002060-200309000-00006; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00002060-200309000-00006; https://dx.doi.org/10.1097/01.phm.0000083671.27501.47; https://insights.ovid.com/ShowUpgradeBrowserMessage
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know